Medtronic plc (MDT)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $bn | - | - | 32 | 31 | 32 | 34 | 36 | 38 |
| Operating profit | $bn | 6 | 7 | ||||||
| Net profit | $bn | - | - | 5 | 4 | 4 | 5 | 5 | 5 |
| EPS reported | $ | 3.73 | 4.06 | ||||||
| Operating cashflow per share | $ | 5.72 | 5.72 | ||||||
| Capex per share | $ | 1.49 | 1.49 | ||||||
| FCF per share | $ | 4.23 | 4.23 | ||||||
| Free cash flow | $bn | 5 | 6 | ||||||
| Net debt | $bn | 19 | 19 | ||||||
| Book value equity | $bn | 49 | 50 | ||||||
| Book value per share | $ | 38.40 | 39.09 | ||||||
| Number of shares | m | 1,288.1 | 1,285.1 | ||||||
| DPS (TTM paid) | $ | 2.15 | 2.86 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 14.83 | 23.76 | ||||||
| P/B LTM | x | 2.16 | 2.15 | ||||||
| P/S LTM | x | 2.91 | 2.88 | ||||||
| P/FCF LTM | x | 19.68 | 17.64 | ||||||
| EV/EBITDA LTM | x | 10.11 | 14.24 | ||||||
| EV/Sales LTM | x | 3.40 | 3.93 | ||||||
| Earnings Yield LTM | % | +7.82% | +4.21% | ||||||
| FCF Yield | % | +5.08% | +5.67% | ||||||
| Quality | |||||||||
| ROE | % | +9.70% | +9.85% | ||||||
| ROIC | % | +6.13% | +6.13% | ||||||
| Operating margin | % | +17.78% | +17.78% | ||||||
| Gross margin | % | +65.02% | +65.02% | ||||||
| FCF/Sales | % | +14.92% | +14.92% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | +3.32% | +47.10% | ||||||
| Sales Growth YoY | % | +8.43% | +16.00% | ||||||
| Net Income Growth YoY | % | +2.96% | +42.27% | ||||||
| FCF Growth | % | +4.65% | +17.92% | ||||||
| Operating Profit Growth | % | +8.60% | +31.92% | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | +3.41% | +3.12% | ||||||
| Dividend Growth | % | -24.03% | +2.51% | ||||||
| Payout Ratio | % | +75.74% | +75.76% | ||||||
| FCF/Debt | x | 0.19 | 0.22 | ||||||
| Net Debt/EBITDA | x | 2.65 | 2.68 | ||||||
| EBIT/Net interest | x | 9.04 | 9.04 | ||||||
| Net debt/market cap | % | +26.12% | +23.88% | ||||||
| Net debt/Equity | x | 0.38 | 0.38 | ||||||
| Gross debt/equity | x | 0.57 | 0.56 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies. These solutions serve healthcare systems, clinicians, physicians, and patients across the world. The company's operations are categorized into several key portfolios: Cardiovascular Portfolio: This segment focuses on cardiac health, providing technologies for heart rhythm management, including implantable pacemakers, defibrillators, and monitoring systems, alongside cardiac ablation tools and remote patient software. It also addresses structural heart issues with products like aortic and pulmonary valves, surgical repair devices, and endovascular stent grafts, in addition to offerings for percutaneous coronary interventions (e.g., angioplasty balloons). Medical Surgical Portfolio: Offering a broad spectrum of surgical instruments and therapies, this division includes staples, vessel sealing devices, wound closure products, and electrosurgical equipment. It also pioneers surgical artificial intelligence and robotic-assisted platforms, alongside solutions for hernia repair, gynecology, lung conditions, minimally invasive gastrointestinal and hepatologic diagnostics, patient monitoring, airway management, ventilation therapies, and renal disease. Neuroscience Portfolio: This division delivers specialized products for a diverse group of medical professionals, such as spinal surgeons, neurosurgeons, neurologists, pain management specialists, and ENT experts. Its offerings span energy surgical instruments, advanced image-guided and intra-operative imaging systems, robotic guidance for spine procedures, and therapies targeting the brain's vasculature. Diabetes Operating Unit: Dedicated to diabetes management, this unit provides innovative solutions like insulin pumps and their associated consumables, continuous glucose monitoring (CGM) systems, and smart insulin pen technologies. Established in 1949, Medtronic plc maintains its corporate headquarters in Dublin, Ireland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free